These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23676589)

  • 21. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
    Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
    Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
    Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF
    Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy.
    Mizoshita T; Ando M; Sagawa H; Mori Y; Katano T; Ozeki K; Tanida S; Okamoto Y; Shimura T; Kubota E; Kataoka H; Kamiya T; Joh T
    Clin J Gastroenterol; 2017 Jun; 10(3):250-254. PubMed ID: 28271435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
    Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
    Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
    J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease.
    Yoo YJ; Chung SY; Gu DH; Ko GJ; Pyo HJ; Kwon YJ; Bak YT; Won NH
    Korean J Gastroenterol; 2014 May; 63(5):308-12. PubMed ID: 24870303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab for the treatment of pediatric Crohn's disease.
    Nuti F; Fiorino G; Danese S
    Expert Rev Clin Immunol; 2015; 11(9):963-72. PubMed ID: 26211396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
    Schreiber S; Reinisch W; Colombel JF; Sandborn WJ; Hommes DW; Robinson AM; Huang B; Lomax KG; Pollack PF
    J Crohns Colitis; 2013 Apr; 7(3):213-21. PubMed ID: 22704916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successfully multiple pregnancies in Crohn's disease under long-term treatment with adalimumab.
    Tursi A
    Acta Gastroenterol Belg; 2013 Jun; 76(2):264-5. PubMed ID: 23898572
    [No Abstract]   [Full Text] [Related]  

  • 34. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.
    Cortes X; Borrás-Blasco J; Antequera B; Fernandez-Martinez S; Casterá E; Martin S; Molés JR
    J Clin Pharm Ther; 2017 Apr; 42(2):234-236. PubMed ID: 28004853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.
    Orlando A; Renna S; Mocciaro F; Cappello M; Di Mitri R; Randazzo C; Cottone M
    Inflamm Bowel Dis; 2012 May; 18(5):826-31. PubMed ID: 21837774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.